Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer (ARETTA)

NCT03879577 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03879577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03879577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer (ARETTA)
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 25, 2019
Completion date
September 30, 2026
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer female, breast cancer stage ii, breast cancer stage iii, her2-positive breast cancer